Register
TNF Inhibitors May Diminish COVID-19 Severity |
Journal Updates
eMediNexus Coverage from: 
TNF Inhibitors May Diminish COVID-19 Severity

0 Read Comments                

Patients on a tumor necrosis factor inhibitor for rheumatic disease when they contracted COVID-19 infection had considerably lesser odds of subsequently requiring hospitalization, suggests early evidence from the COVID-19 Global Rheumatology Alliance Registry.

Contrarily, the registry patients taking 10 mg prednisone or more daily when they got infected had more than double the odds of being hospitalized than those who were not on corticosteroids, even after controlling for the severity of their rheumatic disease and other potential confounders, Jinoos Yazdany, MD, reported at the virtual edition of the American College of Rheumatologys 2020 State-of-the-Art Clinical Symposium… (Medscape)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now